Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart + Anlotinib vs Tislelizumab in First-line Advanced Squamous NSCLC
NCT05718167Phase 3Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib in squamous cell carcinoma of the lung (SCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
squamous cell carcinoma of the lung (SCC)
Beyond the preview
Go deeper on NCT05718167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718167.